Background. Tumor-associated macrophages (TAMs) can either promote angiogenesis (i.e., the formation of new blood vessels) in tumors by secreting tumor necrosis factor-␣ (TNF-␣) or inhibit angiogenesis by producing granulocyte-macrophage colony-stimulating factor (GM-CSF), which in turn stimulates production of the antiangiogenic protein plasminogen activator inhibitor type 2 (PAI-2). We tested, alone or in combination, the anti-prostate cancer activity of agents that perturb macrophage function. Methods: By use of enzyme-linked immunosorbent assays, we measured the effects of Linomide® (roquinimex), thalidomide, pentoxifylline, and genistein on TNF-␣ and GM-CSF production in vitro by virally transformed RAW 264.7 mouse macrophages and on PAI-2 production in vitro by human macrophages. The antitumor effects of these agents were tested in vivo on transplanted Dunning R-3327 MAT-Lu rat prostate cancers; TAM numbers and blood vessel densities in these cancers were determined by use of immunocytochemistry. Results: Linomide selectively inhibited mouse macrophage secretion of TNF-␣ but not of GM-CSF; however, thalidomide, pentoxifylline, and genistein inhibited the production of both cytokines. Linomide, but not thalidomide or pentoxifylline, increased production of PAI-2 by human macrophages. When administered to rats bearing MAT-Lu tumors, each of the tested agents reduced TAM numbers (Linomide, by 46%; thalidomide, by 94%; pentoxifylline, by 71%; and genistein, by 96%). However, all of the agents reduced tumor blood vessel density and
and is often activated during the early, preneoplastic stages of tumor development (1, 2) . Thus, the inhibition of angiogenesis should be highly effective in inhibiting the growth of solid tumors. Tumor angiogenesis is controlled by a number of positive and negative regulators elaborated by tumor cells and tumorassociated host cells, particularly by tumor-associated macrophages (TAMs) (3) (4) (5) (6) (7) . When TAMs become activated in response to appropriate stimuli, these immune cells play a key role in tumor angiogenesis by secreting a repertoire of substances that promote angiogenesis. Some of these products include proteases, growth factors (e.g., acidic fibroblast growth factor [aFGF] , basic fibroblast growth factor [bFGF] , vascular endothelial growth factor [VEGF] , granulocytemacrophage colony-stimulating factor [GM-CSF], transforming growth factor-␣, and insulin-like growth factor-I), and other cytokines (e.g., tumor necrosis factor-␣ [TNF-␣], interleukin 6, and interleukin 8). Thus, TAMs have the ability to affect each phase of the angiogenic process, including degradation of the extracellular matrix, endothelial cell proliferation, and endothelial cell migration.
TAMs also have the ability to inhibit angiogenesis, by the production of specific inhibitors of plasminogen activator (PA). Urokinase-type plasminogen activator (uPA) has been found to be induced by angiogenic factors in migrating capillary endothelial cells (8) . In breast cancer, high levels of uPA are associated with more aggressive cancers, due to a positive association between microvessel density, blood vessel invasion, and uPA content (9) (10) (11) . In contrast, high levels of a specific inhibitor of uPA, termed plasminogen-activator inhibitor type 2 (PAI-2), are associated with a favorable prognosis (12) . In a subendothelial cell matrix model, matrix degradation induced by a colon cancer cell line that produces uPA is inhibited by the addition of PAI-2 (13) . Further studies have demonstrated that GM-CSF can stimulate PAI-2 production by macrophages (14) and that inoculation into animals of prostate cancer cells that have been genetically altered to overproduce GM-CSF completely suppresses tumor growth in a mouse model (15) . Together, these studies demonstrate that TAMs can have both positive and negative effects on tumor angiogenesis. Thus, any agent that attempts to inhibit angiogenesis by means of affecting TAMs within the growing cancer should inhibit the positive effects of TAMs on tumor angiogenesis without eliminating the negative effects.
Linomide® (roquinimex; N-phenylmethyl-1,2-dihydro-4-hydroxyl-1-methyl-2-oxo-quinoline-3-carboxamide) is an orally active agent that consistently inhibits growth of all of a large series of both rodent and human prostate cancer xenografts tested in vivo (16) (17) (18) . Linomide's antitumor effects are due to its ability to inhibit tumor angiogenesis, as demonstrated by a decrease in the number of tumor blood vessels and a consequent re-duction in tumor blood flow in Linomidetreated tumor-bearing rats (19, 20) . Treatment of tumor-bearing rats with Linomide reduces the number of TAMs within prostate cancers and also the ability of macrophages to synthesize and secrete TNF-␣ (21, 22) . Linomide's inhibition of tumor angiogenesis results in a greater than 50% reduction in prostate cancer growth (16) . To increase the magnitude of this growth reduction, it may be possible to combine Linomide with other chemotherapeutic agents. With the use of several prostate cancer model systems, we have demonstrated that, when combined with Linomide, androgen ablation potentiates the inhibition of tumor growth (23) by its ability to induce directly the programmed (apoptotic) death of androgen-dependent prostate cancer cells (24) as well as by its ability to inhibit tumor angiogenesis through reduction of VEGF production by these cancer cells (25, 26) . These observations suggest that Linomide could be combined, not only with androgen ablation, but with other antiangiogenic agents to achieve greater therapeutic effects. In particular, combining Linomide with other antiangiogenic agents of the class known to inhibit TAM function might produce a better therapeutic effect against prostate cancer than would monotherapies with these agents. At present, there are at least three additional antiangiogenic agents known to inhibit macrophage function. These include thalidomide (27, 28) , genistein (27, 29) , and pentoxifylline (28, 30) . Thus, in the present study, we compared the ability of Linomide, thalidomide, pentoxifylline, or genisteinalone and in combination-to inhibit the in vivo growth of the Dunning R3327 MAT-Lu rat prostate cancer.
MATERIALS AND METHODS
Reagents. Linomide was generously provided by Pharmacia and Upjohn (Lund, Sweden); genistein, pentoxifylline, and lipopolysaccharide (LPS) from Escherichia coli serotype 0121:B8 were purchased from Sigma Chemical Co. (St. Louis, MO); and thalidomide was provided by Dr. Georgia Vogelsang of The Johns Hopkins Oncology Center (Baltimore, MD). For in vivo experiments Linomide, thalidomide, and pentoxifylline were dissolved in sterile isotonic saline and delivered daily via subcutaneous injections in the animal's flank. Genistein was dissolved in 100 mM sodium carbonate and administered daily by subcutaneous injection. For in vitro experiments, stock solutions (10 mg/mL) of thalidomide, pentoxifylline, and genistein were prepared in dimethyl sulfoxide. Linomide (10 mg/mL) was dissolved in phosphate-buffered saline (PBS).
Cell preparation and culture. The cell line used for these studies, the Dunning R3327 MAT-Lu, is an androgen-independent, anaplastic, highly metastatic, rat prostate cancer cell line capable of serial passage, both in cell culture and in vivo, in inbred Copenhagen (Cop) rats. The developmental history of the cell line has been described previously (31) . This cell line is maintained in RPMI-1640 medium containing 10% fetal bovine serum (FBS, HyClone Laboratories, Inc., Logan, UT) at 37°C. RAW 264.7 is an Abelson leukemia virus transformed, murine monocyte-macrophage line obtained from American Type Culture Collection (ATCC) (Manassas, VA). RAW 264.7 cell were grown in Dulbecco's modified Eagle medium (DMEM, Life Technologies, Inc. [GIBCO BRL], Gaithersburg, MD), supplemented with 50 mg/mL gentamicin and 10% fetal bovine serum. All experiments were performed using cells that were exposed to the relevant drugs for 7 days. A previous study (22) demonstrated that a minimum of 325 M Linomide was required to inhibit RAW cell TNF-␣ secretion. Therefore, for all of the in vitro studies, 325 M Linomide was used. Thalidomide was used at 78 and 194 M, while pentoxifylline was used at 72 and 180 M, because a previous study (28) demonstrated that these doses produced a greater than 50% dose-dependent inhibition of macrophage TNF-␣ secretion. Genistein was used at a concentration of 100 M, because a previous study (32) demonstrated that at this concentration, genistein was also able to inhibit TNF-␣ production by monocytes by more than 50% from baseline. Human peripheral blood mononuclear cells (PBMCs) were harvested from the venous blood of healthy volunteers at The Johns Hopkins Hospital Hemophoresis facility. Mononuclear cells were separated using lymphocyte separation medium (Organon Teknika Co., Durham, NC), following the manufacturers protocol. The cells were resuspended in complete medium as described previously (33) .
Sample preparation. RAW cells exposed to test agents for 7 days were washed once and fresh medium containing the same concentrations of each drug were added to the cultures. After 4 additional hours, the conditioned medium was collected, centrifuged at 1000g for 10 minutes at 4°C to remove cellular debris, aliquoted, and stored at −70°C until assayed for GM-CSF and TNF-␣ levels. On removal of the conditioned medium, the cells were scraped and the dishes washed with Hanks' balanced salt solution to remove all of the cells. An aliquot of suspended cells was used to count the total number of cells present using a Coulter electronic particle counter (Coulter Corp., Hialeah, FL). As controls, conditioned medium was similarly obtained from RAW cells not exposed to any agent. The PBMCs were transferred to polypropylene tubes, treated with Linomide (163 and 325 M), thalidomide (194 M), pentoxifylline (180 M), or with medium alone (control) and incubated at 37°C in a 5% CO 2 atmosphere for 24 hours. At the end of incubation, the cells were centrifuged at 450g for 10 minutes at 4°C and the cell pellets were separated and lysed in sterile water and then subjected to repeated freeze thaw cycles to liberate the cytoplasmic contents. The cell lysates were centrifuged at 450g at 4°C, and the supernatants were stored at −70°C until assayed for PAI-2.
GM-CSF, PAI-2 and TNF-␣ enzyme-linked immunosorbent assay (ELISA). Samples stored at -70°C were thawed and diluted appropriately. GM-CSF and TNF-␣ concentrations were determined by ELISA following the protocol provided by the kit manufacturer (Endogen, Cambridge, MA) while PAI-2 concentrations were determined using the protocol provided by American Diagnostica Inc. (Greenwich, CT). Results for the conditioned media and cell lysates were expressed as amount of GM-CSF, PAI-2, and TNF-␣ per 10 6 cells. Animals. The animals used in these studies were maintained in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals, and the specific protocols were approved by The Johns Hopkins Medical Institutions Animal Care and Use Committee. Inbred Copenhagen male rats were obtained from Harlan Sprague-Dawley, Inc. (Indianapolis, IN) and housed in groups of three to four animals per individual microisolater cage under controlled light (12 hours light, 12 hours dark; lights set at 0700 hours), temperature (21-22°C), and humidity (50%). Food (Rat Chow; Purina Mils, Inc., Richmond, IN) and water were available ad libitum.
Tumors. To produce tumors in Copenhagen rats, 1 × 10 6 Mat-Lu cancer cells were injected subcutaneously into the flank region under Metofane (Mallinckrodt Veterinary Inc., Mundelein, IL) anesthesia. Following the development of tumors of 0.1-cm 3 size, the rats were randomly assigned to control and treatment groups (n ‫ס‬ 6-7 animals/group) and started on the drugs. The animals were given either Linomide (81 mol/kg per day), thalidomide (194 mol/kg per day), pentoxifylline (108 mol/kg per day), or genistein (80 mol/kg per day). We have observed 81 mol/kg per day to be the maximally effective dose for Linomide. Thus, for combination experiments, we used the other drugs at equimolar concentrations to this dose of Linomide. At various intervals following tumor inoculation, the individual tumor dimensions were measured serially using calibrated microcalipers. Tumor volumes in cubic centimeters were calculated using the formula (l × w × h) × 0.5236 as described previously (31) .
Quantitation of tumor-infiltrating macrophages and blood vessel density. After 3 weeks of daily treatment of MAT-Lu tumor-bearing rats with vehicle or test agents, animals were killed and their tumors were harvested, weighed, fixed with 10% buffered formalin, and embedded in paraffin; tissue sections were then prepared. To quantitate the number of TAMs, tissue sections were immunohistochemically stained with ED2 monoclonal antibody (Harlan Bioproducts For Science, Indianapolis, IN), which is specific for a cell-surface antigen on macrophages as described previously (21) . The slides were examined by low-power magnification (10×) and 10 random fields per slide were selected. The mean number of TAMs per high power field (i.e., 400×) was calculated from the 10 randomly selected fields. To quantitate the tumor blood vessel density, tissue sections were immunocytochemically stained for factor VIII-related antigen (Dako Corp., Carpinteria, CA) as described previously (20) . These slides were analyzed using the Computerized Image 1 Analysis system (Universal Image Corporation, Westchester, PA) as described previously (20) . The mean area of neovessels, expressed as the percent of a 200× field, was calculated from 20 randomly selected fields.
Statistical analysis. Data are presented as mean ± standard deviation (SD) Linomide inhibits TAM function as part of its mechanism of antitumor/ antiangiogenic action. To test whether combination therapy with Linomide plus additional drugs that also inhibit TAM function might be more effective than monotherapy against the growth of prostate cancers in vivo, we validated the ability of thalidomide, pentoxifylline, and genistein to inhibit TAM function by use of the RAW 264.7 mouse macrophage cell line in an in vitro test system. In the present study, exposure of RAW cells in vitro to the chosen concentrations of thalidomide, pentoxifylline, or genistein significantly inhibited the cells' baseline ability to secrete TNF-␣ (Table 1) , even though the concentrations used were much lower than that of Linomide.
Additional studies (14, 15, 33) have demonstrated that GM-CSF has the ability to stimulate the invasive and chemotactic properties of mature monocyte/ macrophages and stimulate antitumor immunity in other types of tumors. We tested whether Linomide, thalidomide, pentoxifylline, or genistein inhibited the ability of RAW cells to secrete GM-CSF and found that exposure of RAW cells to thalidomide, pentoxifylline, or genistein in vitro significantly inhibited LPSinduced secretion of GM-CSF by these cells (Table 1 ). In contrast, Linomide, even at a higher concentration than these other drugs, did not inhibit GM-CSF secretion.
In a previous study (16) , the growth of a variety of rat and human prostate cancer cell lines was not inhibited when these cells were exposed directly to Linomide at concentrations as high as 1 mM during culture in vitro. To test whether the other agents could directly inhibit the growth of prostate cancer cells in vitro, we used the MAT-Lu rat prostate cancer cell line as a model. This cell line was used because it is androgen independent and highly metastatic, mimicking the most lethal form of prostate cancer (31) . Viable MAT-Lu cells (2 × 10 4 ) were inoculated into four flasks per group and allowed to attach overnight before being exposed to either control media or media containing the following: 325 M Linomide, 78 M thalidomide, 72 M pentoxifylline, or 100 M genistein. The respective media were replaced every 2 days and, after a total of 6 days of exposure, the number of viable MAT-Lu cells in each flask was counted. These results demonstrated that the difference in mean cell numbers (×10 6 ) was not statistically significant for the control (3.37 ± 0.24), thalidomide-(3.53 ± 0.10), or pentoxifylline-treated (3.29 ± 0.16) groups. In contrast, Linomide (2.86 ± 0.20) and genistein (0.46 ± 0.04) each significantly (P ‫ס‬ .003) decreased the growth of these cells compared with cells exposed to control media. These results demonstrate that, except for Linomide and genistein, all of the other agents studied are neither cytotoxic or cytostatic to the MAT-Lu rat prostate cells at doses that are effective in perturbing the RAW cell's ability to secrete GM-CSF and/or TNF-␣.
Effects of the Various Agents on the Number of TAMS, on Tumor Blood Vessel Density, and on Growth of MAT-Lu Prostate Cancers In Vivo
To document that each of the agents that we found to influence RAW macrophage function in vitro also had an effect on macrophages in vivo, rats bearing MAT-Lu rat prostate cancer were treated with each of these agents daily for 3 weeks before we harvested the tumor for TAM determination. Our findings documented that each of these agents decreased TAM number, tumor blood vessel density, and tumor growth ( Table 2) . Although thalidomide, pentoxifylline, and genistein are more potent inhibitors of the secretion of TNF-␣ and GM-CSF by Raw cell in vitro (Table 1 ) and more effective inhibitors of TAM number in MAT-Lu cancers in vivo than was Linomide, this latter agent was the most effective in lowering tumor blood vessel density and reducing tumor growth in vivo (Table 2) .
To determine whether combinations of the other antiangiogenic agents with Linomide could further suppress tumor growth, rats bearing MAT-Lu prostate cancer were treated daily with Linomide plus each of the other agents at the doses used in the monotherapy experiments. Combination experiments with Linomide plus genistein demonstrated no additional suppression of MAT-Lu growth beyond that produced by Linomide alone. In contrast, combination of Linomide and either thalidomide or pentoxifylline, significantly (P ‫ס‬ .03; n ‫ס‬ 6-7 observations/ group) inhibited a portion of the antitumor effect of Linomide monotherapy (i.e., 35% ± 11% and 50% ± 12% inhibition of the Linomide monotherapy effect at 21 days of treatment, respectively). Fig. 1 documents this inhibitory effect of the combination of Linomide and pentoxifylline.
Effect of Linomide, Thalidomide, or Pentoxifylline on PAI-2 Production by Macrophages
The results given above demonstrate that daily treatment with pentoxifylline or thalidomide decreased TAMs in the MAT-Lu cancers to a greater extent than did daily treatment with Linomide, even though Linomide monotherapy produced greater tumor antiangiogenesis and a greater overall antitumor effect ( Table 2) . The inhibition in the number of TAMs is probably due to the inhibition of GM-CSF macrophage secretion by thalidomide and pentoxifylline. In contrast, Linomide's ability to inhibit TAM number is clearly not mediated by changes in GM-CSF production by macrophages.
GM-CSF is known to increase the expression of PAI-2 at both the messenger RNA and protein levels (14) . Thus, the decrease in macrophage production of GM-CSF induced by thalidomide and pentoxifylline should result in a decrease in the production of PAI-2 protein by TAMs within the growing prostate cancer. Decreased production of PAI-2 by TAMs would allow more of the uPA in the extracellular fluid to be active and thus to stimulate tumor angiogenesis by allowing endothelial cell migration (8, 9, 11, 13) . To test this possibility, human macrophages were treated with thalidomide or pentoxifylline in vitro for 24 hours and cell lysates were then assayed for PAI-2 content. Human macrophages were used because there is no ELISA assay for rodent PAI-2 at this time. These studies demonstrated that both thalidomide and pentoxifylline inhibit PAI-2 production (Table 3 ). In contrast, as has been previously demonstrated (33) , Linomide stimulates human macrophages to produce PAI-2 (Table 3) . Since uPA activity is involved in macrophage migration (5, 6) , increased production of PAI-2 should lower the uPA activity, thus inhibiting macrophage infiltration of the tumor. In addition, the enhanced production of PAI-2 by the TAMs that do infiltrate tumors in Linomide-treated animals should also inhibit endothelial migration, which is known to require uPA activity (8) .
DISCUSSION
TAMs play a dual role in tumor angiogenesis and tumor growth by the release of proteases, growth factors, and cytokines. These cells can either stimulate tumor growth via their release of proteases and angiogenic tumor growth factors (e.g., TNF-␣) or inhibit growth via production of antiangiogenic protease inhibitors (e.g., PAI-2). The class of antiangiogenic agents that we tested in this study all affect such macrophage functions. All four of the agents tested inhibit the secretion of the angiogenic molecule, TNF-␣, by macrophages. Thalidomide, pentoxi- fylline, and genistein also inhibit the secretion of GM-CSF by macrophage. Due to these effects, these three agents decrease the number of TAMs within the prostate tumor and thus decrease the production of angiogenic factors within the tumor, which results in an antiangiogenic and thus an antitumor effect. Other studies have demonstrated that these antiangiogenic agents can inhibit tumor angiogenesis by affecting other cytokines involved in angiogenesis. For example, genistein has been shown to block VEGFinduced proliferation of endothelial cells by inhibiting tyrosine phosphorylation of signaling molecules that contain SH2 domains (34) . Thalidomide has also been demonstrated to inhibit both VEGF-and bFGF-induced angiogenesis in the rabbit corneal micropocket assay (35) . Thus, it is possible that such mechanisms may also contribute to the antiangiogenic and antitumor effect of these agents.
In contrast to the other three agents, Linomide has no effect on GM-CSF production by macrophages while it inhibits TNF-␣ secretion by these cells. A previous study (14) has demonstrated that GM-CSF can up-regulate PAI-2 production by macrophages. For this reason, the inhibition of GM-CSF production by thalidomide, pentoxifylline, or genistein may not be advantageous, because the resultant inhibition of PAI-2 production by TAMs may facilitate the angiogenic process. Linomide, on the other hand, has the advantage that it decreases the production and secretion of angiogenic factors (i.e., TNF-␣) while it has no effect on GM-CSF levels and, in addition, it stimulates PAI-2 production by TAMs. Increased PAI-2 production should result in a greater inhibition of uPA within the tumor, thus further inhibiting angiogenesis. Enhanced PAI-2 production and the subsequent inhibition of uPA would appear critical for Linomide's mechanism of action: When Linomide is combined with thalidomide or pentoxifylline (which decrease both TAM number and PAI-2 production), a portion of Linomide's antitumor effect is inhibited. To understand these interactions, we have performed binding studies using RAW and human microvascular endothelial cells. These studies have not demonstrated the presence of a highaffinity binding site for Linomide (data not shown). Thus, pentoxifylline or thalidomide's ability to inhibit Linomide's antitumor effects do not appear to be due to an inhibition of Linomide's interaction with high-affinity binding sites. However, the possibility that both Linomide and pentoxifylline would compete for a lowaffinity common target cannot be excluded.
Linomide not only inhibits TNF-␣ secretion and stimulates PAI-2 production by macrophages but, as previously demonstrated, it also inhibits endothelial cell migration and invasion in vitro (19) and angiogenesis in vivo, induced by angiogenic molecules that are produced directly by prostate cancer cells (e.g., VEGF, bFGF, aFGF, and TNF-␣) (18) . Another study (36) has also demonstrated that Linomide can inhibit VEGF-induced endothelial cell growth and migration. Therefore, Linomide inhibits multiple steps in the angiogenic process and this influence involves inhibitory effects on endothelial cells directly as well as both stimulation and inhibition of TAM function. Although both thalidomide and genistein also inhibit angiogenesis via other mechanisms than those that affect macrophage function, these agents neither produce better antitumor effects than Linomide as single agents nor do they potentiate the antitumor effect of Linomide when combined with it. Thus, when combining Linomide with other antiangiogenic agents, it will be important to ensure that the additional agents do not decrease Linomide's stimulation of PAI-2 production by TAMs. Our findings suggest that Linomide's unique properties could make it more effective against prostate cancer than other antiangiogenic agents that we tested.
